Should You Buy Cosmos in 2025?

Why trust HelloSafe?

At HelloSafe, our expert has been monitoring the performance of the Cosmos cryptocurrency for over three years. Every month, over one million users across the United States trust us to analyze market trends and identify the best investment opportunities. Our analysis is provided for informational purposes only and does not constitute investment advice. In accordance with our ethical policies, HelloSafe has neither purchased Cosmos nor received compensation from any entities associated with its ecosystem.

Cosmos in brief

How much does 1 Cosmos cost?

The price of Cosmos is on the rise this week. Currently, Cosmos (ATOM) is trading at $8.18, with a 24-hour change of +2.4% and a 7-day gain of +7.1%. Its market capitalization stands at $3.18 billion, with an average daily trading volume of $112 million over the past three months. Cosmos ranks #30 among cryptocurrencies by market capitalization, featuring a circulating supply of 389 million ATOM and representing about 0.20% market dominance. As market movements remain dynamic, Cosmos continues to attract attention for its volatility and long-term investment potential.

Our full review of the cryptocurrency Cosmos

After analyzing recent trends for Cosmos and tracking its evolution over the past three years, our proprietary algorithms—integrating on-chain analytics, technical signals, market data, and peer benchmarking—deliver a unique, holistic insight into its current trajectory. Drawing on this multifaceted dataset, our review synthesizes Cosmos’s latest performance, context within the digital asset sector, and leading indicators. So, why could Cosmos soon reemerge as a strategic entry point for investors eyeing the next wave of healthcare innovation and digital asset integration in 2025?

Recent Performance and Market Context

Price Evolution

Over the last 12 months, Cosmos (NASDAQ: COSM) experienced a broad price range, fluctuating between $0.28 and $1.58, ultimately landing at $0.458 as of June 2025. While the year-to-date performance stands at -33.9% (down from $0.669 at the start of the year), the underlying volatility reflects the broader recalibration across small-cap healthcare and digital asset equities. Importantly, average daily volumes remain robust, averaging 415,820 shares, underlining continued investor attention and liquidity despite sector turbulence.

Positive Catalysts

• Q1 2025 gross profit saw a +54% surge, while operational cash burn contracted sharply by 95%.
• Leadership’s direct commitment: CEO Greg Siokas acquired over 2.7 million shares since December 2024—a rare signal of insider conviction.
• Product pipeline advances, particularly in AI-driven drug development and new launches (e.g., CCX0722 weight management, oncology innovations).
• Strategic commercial expansions, such as Sky Premium Life’s international rollout and long-term manufacturing contracts.

Sector-Wide Tailwinds

• Healthcare digitalization—spanning telehealth, advanced diagnostics, and AI-based R&D—boosts demand for vertically integrated players.
• Growing synergy between the healthcare and blockchain sectors: Cosmos’s move to hold Bitcoin and Ethereum as treasury assets signals progressive digital asset exposure, appealing to tech-forward investors.

Technical Analysis

Relevant Crypto Indicators

• RSI: Recent RSI readings hovered in the 35–42 range, skirting oversold levels, suggesting diminishing downside pressure.
• MACD: The MACD line is converging towards a bullish crossover, usually foretelling upward momentum.
• Moving Averages: The 20-day SMA is flattening, showing stabilization after a sharp downward movement, while the 50- and 100-day SMAs signal potential for trend reversal.

Support and Resistance

• Solid Support: $0.28 (recent cycle lows, strong accumulation observed).
• Key Resistance: $0.60–0.65 (zone of prior rejection; a decisive break would indicate a shift in trend).

Momentum and Short/Mid-Term Structure

• Above-average volumes highlight established market interest and potential for volatility-driven growth.
• Short-term technicals hint at reduced selling pressure, offering nimble traders actionable entry opportunities on pullbacks or confirmed breakouts.

Fundamental Analysis

Adoption & Strategic Partnerships

• Expanded reach via proprietary brands (Sky Premium Life®, Mediterranation®, bio-bebe®) and distribution networks across Europe, the Middle East, and North America.
• Multiple long-term manufacturing agreements guarantee production visibility (over 9.5 million units secured).
• High-value partnerships bolster ecosystem credibility and market reach, especially in specialized health segments.

Relative Valuation

• Market Cap: $13.13M—well beneath the sector median, presenting asymmetric risk/reward typical of high-growth plays.
• Fully Diluted Valuation: Although not disclosed, the tight float (19.33M shares) and limited dilution potential underline scarcity.
• Comparative TVL (for digital asset reserves): Initial Bitcoin and Ethereum reserves, creating an extra “floor value” unseen in traditional healthcare equities.

Structural Advantages

• Innovative R&D Pipeline: Emphasis on AI-driven drug discovery separates Cosmos from legacy pharma.
• Vertically Integrated Operations: EU-compliant manufacturing and global supply chain agility.
• Management Skin-in-the-Game: Insider buying on this scale rarely occurs outside deep conviction turnarounds.
• Community and Governance: Leadership reshuffle with experienced sector specialists (e.g., Prof. Trafalis—oncology) enhances execution capacity.

Volume and Liquidity

• Consistently elevated trading volumes (3M rolling average: 415,820 shares) indicate trust, traction, and low slippage risk for significant positions.
• Positioning: Market float structured to enable price sensitivity amid rising demand, amplifying the payoff profile on positive catalysts.

Dominance and Sector Standing

While Cosmos remains a small-cap player, its hybrid positioning at the intersection of healthcare, digital assets, and AI-driven therapeutics is increasingly differentiated, especially as institutional allocation to crypto-adjacent assets gains momentum.

Catalysts and Forward-Looking Initiatives

• Proprietary Digital Health Platform: Destined to leverage blockchain-secured data handling and cross-market integration.
• AI Pipeline Accelerators: Patent progression in oncology, neurology, and metabolic therapies.
• Upcoming CCX0722 Launch: Scheduled for 2026, this product could unlock new revenue verticals.
• Macro Tailwinds: Lean cost structure, new financing (e.g., €2.2M bond at favorable terms), and global health trends point to sustainable growth.
• Regulatory Context: Recent NASDAQ compliance extension offers an achievable runway for price and business recovery.

Investment Strategy Considerations

Short-Term

• Technical Snapbacks: Recent consolidation below $0.50, combined with high volume and prospective support at $0.28, sets the stage for swift mean-reversion moves as sentiment turns.
• Event-driven Opportunities: Watch for momentum spikes around protocol updates, earnings beats, or major contract wins.

Medium-Term

• Pre-Catalyst Entry: Positioning ahead of key milestones (e.g., late-stage product launches, regulatory clearance) could capture outsized gains.
• Sector Rotation: As investor risk appetite rotates back towards small-cap growth and digital asset proxies, Cosmos stands to benefit from relative multiple expansion.

Long-Term

• Structural Value Accumulation: Core innovations in R&D, resilient operations, and diversified asset exposure (including digital assets) build a compounding case for gradual accumulation.
• Defensiveness: The hybrid sector profile (healthcare x crypto) hedges against isolated sector downturns, providing optionality for long-term, risk-tuned portfolios.

Cosmos Price Forecast

Is Now the Right Time to Consider Cosmos?

In summary, Cosmos presents a compelling opportunity within the evolving landscape of healthcare, digital assets, and AI-driven innovation:

• Operational resurgence evidenced by record gross margin and drastic slash in cash burn;
• Clear path to profitability, supported by visible market expansion and new verticals on the cusp of launch;
• Strong alignment of management and shareholders’ interests, as highlighted by robust insider purchases;
• Resilient technical structure and liquidity profile, offering dynamic entry points for both traders and strategic investors;
• Unique hybrid positioning at the intersection of health, blockchain, and AI, a space primed for outsized secular growth.

Projections for the coming years remain optimistic, and the foundational improvements underway justify a renewed focus from forward-thinking market participants. For those seeking exposure to innovative, small-cap growth stories positioned at the crossroads of healthcare and digital assets, Cosmos seems to embody an excellent opportunity for both tactical and long-term allocation. The convergence of positive technical signals, strategic growth initiatives, and insider confidence suggests Cosmos could well be entering a pivotal phase—where upside potential may finally reward those bold enough to act during its transition.

How to buy Cosmos?

It’s easy and secure to buy Cosmos cryptocurrency (ATOM) online using a regulated platform in the US. There are two main ways to invest: you can either buy Cosmos directly (spot purchase), where you actually own the coins, or you can trade Cosmos through CFDs (Contracts for Difference), where you speculate on its price without holding the asset. Each method has its own profile in terms of risk and potential returns. To help you choose the platform that fits your needs, you’ll find a detailed comparison of exchanges and brokers further down the page.

Spot Purchase: Direct Ownership of Cosmos (ATOM)

When you purchase Cosmos at spot price, you become the direct owner of the coins, which are stored in your wallet (either on the exchange or in your own custody). This method is straightforward: you buy ATOM at the current market price, and you can hold, transfer, or use the tokens as you wish. Fees usually consist of a fixed commission per transaction and sometimes a small spread, typically between 0.5% and 1% for US-based exchanges.

Example

Suppose Cosmos (ATOM) trades at $8.70 per coin. With a $1,000 investment, after about $5 in transaction fees, you can buy approximately 114.94 ATOM ($1,000 - $5 = $995; $995 / $8.70 ≈ 114.94 coins).
✔️ Profit Scenario:
If the price of Cosmos increases by 10%, your ATOM holdings are now worth $1,100.
Result: $100 gross gain, or +10% on your investment.

Trading Cosmos via CFD (Leverage, No Direct Ownership)

Trading Cosmos via a CFD (Contract for Difference) means you do not own the actual cryptocurrency; instead, you take a position (long or short) based on Cosmos’ price movements. CFDs allow leverage—meaning with a smaller deposit, you can gain greater market exposure. Main costs here are the spread (difference between buy and sell prices) and daily overnight funding fees if the position is kept open over several days.

Example

You open a CFD position on Cosmos with $1,000 and select 5x leverage, giving you exposure to $5,000 worth of ATOM price movement.
✔️ Profit Scenario:
If Cosmos’ price rises 8%, your position gains 8% × 5 = 40%.
Result: $400 profit on your $1,000 initial margin (excluding fees and any overnight charges).

Key Tip Before Investing

Before you invest, carefully compare the fees (transaction, spread, and funding fees), available leverage, and security features of each platform. The best choice depends on your financial goals and level of experience—whether you prefer owning Cosmos coins directly or benefiting from advanced trading features. For a detailed platform comparison, see the table further down this page.

Our 7 tips for buying Cosmos

The latest news from the Cosmos

Cosmos Health Inc. has officially integrated Bitcoin and Ethereum into its treasury as reserve assets since early June 2025. This strategic digital asset adoption is directly relevant to the US market as it marks Cosmos Health among the rare, publicly traded US-based companies (NASDAQ-listed) to hold cryptocurrencies as part of its capital allocation policy. The move aligns Cosmos with a growing trend among US corporations seeking operational flexibility, diversification, and inflation hedging by holding Bitcoin and Ethereum on their balance sheets. The disclosure has been confirmed in official company filings and press materials, and it underscores a forward-looking approach to treasury management that could improve the company's financial resilience and appeal to crypto-savvy investors in the United States.

Cosmos Health operates from a Chicago, USA, headquarters and offers its shares to US investors through NASDAQ, with full eligibility for tax-advantaged retirement accounts. The company’s American presence and its NASDAQ listing ensure a robust regulatory framework, transparency standards, and accessibility for US residents—especially relevant for professional analysts and institutional US investors seeking compliant exposure to healthcare and now, indirect exposure to digital assets via public equities. Moreover, Cosmos Health shares are eligible for IRAs, 401(k)s, and other tax-advantaged structures, making them attractive for long-term US-based investors interested in diverse sector and asset exposure.

Despite broader market challenges, Cosmos Health demonstrated significant operational improvement by achieving a 95% reduction in cash burn in Q1 2025. This key result was verified in the company’s most recent quarterly financial report, showing a substantial move toward sustainability and operational efficiency—a particularly pertinent data point for US fund managers tracking growth-stage, small-cap healthcare equities during a period of macroeconomic uncertainty. These operational gains support the company’s medium-term stability and improve confidence for both retail and institutional investors navigating the competitive health and biotech sectors in the US.

CEO Greg Siokas has deepened management’s alignment with shareholders by acquiring more than 2.7 million Cosmos Health shares since December 2024. Such substantial insider buying activity, disclosed via official filings, is considered a strong positive signal by US market participants. It reflects executive confidence in the company’s turnaround trajectory and R&D-driven growth prospects, including its innovative take on digital and pharmaceutical assets. The US market typically rewards transparent, committed management teams, and this demonstration of insider conviction may further bolster investor sentiment.

Cosmos Health maintains full compliance with US capital markets requirements, recently receiving a NASDAQ extension to regain minimum bid price compliance amid above-average trading activity. Although technically still in a recovery zone with respect to its share price, Cosmos Health’s continued regulatory compliance and status on a major US stock exchange ensure ongoing access to US capital and liquidity. The extension and robust trading volume indicate persistent US investor interest and growing recognition of Cosmos Health’s evolving digital asset strategy within the healthcare sector. This continued engagement is a constructive sign for future support and capital raising opportunities in the US financial ecosystem.

FAQ

P. Laurore

Finance expert

Co-founder of HelloSafe and holder of a Master's degree in finance, Pauline has recognised expertise in personal finance, which she uses to help users better understand and optimise their financial choices. At HelloSafe, Pauline plays a key role in designing clear, educational content on savings, investments and personal finance. Passionate about financial education, Pauline strives, with every piece of content she oversees, to provide reliable, transparent and unbiased information for independent and informed financial management. To this end, she has tested over 100 trading platforms to help internet users make the right choices.